Natural killer T cells are a potent mediator of anti-viral immunity in mice, but little is known about the effects of manipulating NKT cells in nonhuman primates. We evaluated the delivery of the NKT cell ligand, a-galactosylceramide (a-GalCer), in 27 macaques by studying the effects of different dosing (1-100 mg), and delivery modes [directly intravenously (i.v.) or pulsed onto blood or peripheral blood mononuclear cells]. We found that peripheral NKT cells were depleted transiently from the periphery following a-GalCer administration across all delivery modes, particularly in doses of Ն10 mg. Furthermore, NKT cell numbers frequently remained depressed at i.v. a-GalCer doses of >10 mg. Levels of cytokine expression were also not enhanced after a-GalCer delivery to macaques. To evaluate the effects of a-GalCer administration on anti-viral immunity, we administered a-GalCer either together with live attenuated influenza virus infection or prior to simian immunodeficiency virus (SIV) infection of two macaques. There was no clear enhancement of influenza-specific T or B cell immunity following a-GalCer delivery. Further, there was no modulation of pathogenic SIVmac251 infection following a-GalCer delivery to a further two macaques in a pilot study. Accordingly, although macaque peripheral NKT cells are modulated by a-GalCer in vivo, at least for the dosing regimens tested in this study, this does not appear to have a significant impact on anti-viral immunity in macaque models.
Introduction
NKT cells are a small subset of T cells that provide an immune defence against viral infections and cancer. In human and macaque peripheral blood, NKT cells typically comprise 0·01-0·1% of the lymphocyte population [1] . NKT cells respond to glycolipid antigens presented by CD1d, a non-classical major histocompatibility complex (MHC)-like molecule, localized on antigen-presenting cells (APC) such as dendritic cells (DC), monocytes and B cells [2] . Type I NKT cells are referred to as semi-invariant NKT cells due to their common usage of the T cell receptor (TCR) chain Va24-Ja18, paired with a limited repertoire of Vb chains [2] [3] [4] . They have a memory phenotype [5] , and upon stimulation NKT cells produce large amounts of cytokines including interferon (IFN)-g, tumour necrosis factor (TNF), interleukin (IL)-2, IL-4, IL-10, IL-13, IL-17, IL-21 and IL-22 [6, 7] . The cytokines produced by NKT cells lead to concomitant activation of other cells of the immune system such as NK cells, B cells and T cells, leading to a larger cascade of cytokine and chemokine production [2] .
NKT cells are depleted during human immunodeficiency virus (HIV) infection of humans [8] [9] [10] or simian immunodeficiency virus (SIV) infection of macaques [11, 12] . Depletion of the CD4 + subset of NKT cells is most marked, and parallels depletion of the total conventional CD4 + T cells. Depletion of NKT cells correlates with disease progression in both HIV and SIV infection [12, 13] . Whether manipulation of NKT cell numbers or function could modulate HIV or SIV infection is not known.
The prototypical NKT cell ligand a-galactosylceramide (a-GalCer) has been used extensively in mice and human studies to demonstrate immunomodulatory effects in cancers [14] [15] [16] [17] [18] [19] [20] , microbial infections [21] [22] [23] and autoimmunity [24] [25] [26] . NKT cells have also been shown to promote immunity to influenza virus [27, 28] , and a-GalCer has been used successfully in mice to enhance immunity to influenza virus A [29] [30] [31] or other viral infections [32, 33] . a-GalCer administration in combination with DNA vaccination of mice was protective in microbial infections or potent in augmenting T cell responses [34, 35] . Furthermore, mice immunized with a-GalCer together with herpes simplex virus-2 (HSV-2) glycoprotein D via the intranasal or intravaginal routes were protected against lethal HSV-2 intravaginal challenge [36] . Many previous studies have used autologous or syngeneic DC pulsed with NKT cell ligands to activate NKT cells in vivo, reviewed in [37] . Such systems require specialized facilities and will not be widely applicable. In previous studies our laboratory has demonstrated the effectiveness of ex-vivo pulsing of cytotoxic T lymphocyte (CTL) peptides onto macaque peripheral blood mononuclear cells (PBMC) or whole blood (WB) [38, 39] . Presumably, immature blood DC can effectively present the antigen following in-vivo maturation. Whether a simpler system of WB or PBMC delivery of NKT cell ligands is effective in vivo is unknown.
Macaques are a useful primate model for a variety of infectious diseases. However, there is no information on effective conditions to activate or expand NKT cells in macaques and thereby modulate virus infections. We conducted a study of 27 SIV-uninfected macaques to determine conditions suitable for in-vivo activation of NKT cells. We subsequently conducted studies to investigate the efficacy of a-GalCer administration in macaques to augment live-attenuated influenza virus immunity. We then investigated SIV disease progression in macaques administered a-GalCer just prior to SIV infection.
Methods

Study animals
We studied a total of 42 pigtail macaques (Macaca nemestrina) for changes in peripheral NKT cell frequencies in response to a-GalCer administration combined with or without SIVmac251 and/or influenza A virus inoculations. Twenty-seven animals were administered with a-GalCer and NKT cell frequencies and function were observed. Two animals were administered a-GalCer at the same time as live attenuated influenza virus infection, along with 13 control animals that received influenza only, and observed for anti-influenza virus immunity (Table 1) . In another study, two animals were administered a-GalCer prior to SIV infection and observed for SIV infection along with five controls that received SIV only (Table 1 ). All animals expressed the MHC class I allele Mane-A1*08401 (previously named Mane-A*10) [40] . Prior to any procedure, macaques were sedated intramuscularly with ketamine (10 mg/kg). All animals were monitored for any significant changes in weight or behaviour or toxic side effects during the respective studies. All studies were approved by the relevant institutional ethics committees.
Modes of delivery of a-GalCer
a-GalCer (KRN7000; Sapphire Biosciences, Waterloo, Australia) was prepared as described previously [41] . For studies on optimization of expansion of in-vivo NKT cell levels we used a total of 27 healthy, SIV-uninfected macaques. Macaques were assigned randomly into three groups and administered a-GalCer intravenously (i.v.), pulsed onto autologous ex-vivo peripheral WB or pulsed onto autologous freshly prepared PBMC. Seven macaques were given a-GalCer IV at doses of 1, 10 or 100 mg each (Table 1 and Fig. 1 ). Nine macaques were given a-GalCer pulsed onto WB. Peripheral blood (9 ml) was drawn into Na-heparin vacuette tubes from each macaque, incubated with 1 or 10 mg a-GalCer for 1 or 3 h at 37°C with mixing every 15 min, and reinfused into the respective animal. Eleven macaques were assigned to the PBMC group. PBMC, typically 10-20 ¥ 10 6 cells, were prepared from ex-vivo blood of the respective animal by density gradient centrifugation using Ficoll-Paque PLUS (GE Healthcare BioSciences AB, Uppsala, Sweden) and incubated with 1 or 10 mg a-GalCer for 1, 3 or 12 h as above in 2 ml serum-free, RPMI-1640 media. Following a-GalCer administration, sequential peripheral blood was drawn from each macaque according to a schedule shown in Fig. 1 and monitored for NKT cell frequencies, as described previously [12, 41] . 
PMA/ionomycin activation of NKT cells and intracellular cytokine expression
Ex-vivo NKT cells were activated for 4 h with phorbol myristate acetate (PMA) (10 ng/ml) in combination with ionomycin (3 uM) in WB assays at days 0, 9 and 20 post-aGalCer administration, as reported previously [41] , with the addition of monensin (2 uM) for the last 2 h of the activation. Unstimulated controls, containing 0·41% dimethylsulphoxide (DMSO), contained the same percentage of DMSO as stimulated samples and were treated as above. Intracellular IFN-g expression was enumerated as described [41] .
Recombinant influenza SIV vaccination
Construction of three separate live-attenuated influenza A (flu) virus each encoding an SIV epitope restricted by Mane-A1*08401 has been described previously [42, 43] . Animals (n = 15) unexposed previously to a-GalCer or flu were enrolled into this study. Flu-SIV (n = 8), flu-SIV in combination with a single dose of a-GalCer (5 mg) pulsed onto WB for 2 h (n = 2) and control flu (n = 5) inoculations were given four times over 18 weeks (Fig. 4) . Flu-specific antibody response was measured by haemagglutination inhibition (HI) assays, as described by Drs Karen Laurie and Aeron Hurt [42] . A flu-specific CD8 + T cell response to a nucleoprotein epitope was assayed with the Mane-A*10-RA9 tetramer reagent on thawed PBMC of the above 15 animals as well as those from flu-naive macaques (n = 13), as described previously [42] .
SIV infection of macaques
Macaques (n = 2) were given a single dose of a-GalCer (5 mg) pulsed onto WB for 2 h, 2 days prior to SIVmac251 infection with 10 4 TCID50 (Fig. 5 ). Five control animals were also infected with SIVmac251 at the same time. SIV viraemia and CD4 T cell counts were measured as described previously [43] .
Flow cytometry analyses absolute counts of NKT cells
Peripheral blood isolated from macaques was stained with CD1d tetramer (CD1dtet) loaded with an a-GalCer analogue, PBS-44 (kindly provided by Professor Paul Savage (Brigham Young University), CD3 (clone SP34-2; BD Biosciences, San Jose, CA, USA), CD4 (clone L200; BD Biosciences) and CD8 (clone SK1; BD Biosciences). NKT cells were identified by flow cytometry as doublet excluded lymphocytes that are double-positive for CD3 and CD1dtet.
NKT cell numbers were enumerated on a Coulter AC.T diff TM Analyzer (Beckman Coulter, Indianapolis, IN, USA) by measuring total peripheral blood lymphocyte counts.
Statistical analyses
Statistical analyses were performed using spss version 20 (IBM, Chicago, IL, USA). Data were analysed by two-way analysis of variance (anova) in conjunction with Bonferroni's post-hoc test. Where necessary, log10 transformation before anova was performed for the data to pass or tend towards Levene's test for equal variances. Data that were not distributed normally were analysed by Kruskal-Wallis test (Fig. 4b) or Kruskal-Wallis with Mann-Whitney post-hoc test (Fig. 4c) .
Results
a-GalCer administration modulates peripheral blood NKT cell frequencies
Enhancing NKT cell numbers or function is an important goal of immunotherapy strategies. Previous studies endeavouring to activate or expand peripheral blood NKT cell numbers in humans using a-GalCer directly have involved either i.v. injection of a-GalCer in solution [17] , in-vitro expansion of autologous PBMC with a-GalCer in the presence of IL-2 and granulocyte-macrophage colonystimulating factor (GM-CSF) [15, 16, 44, 45] or purified DCs pulsed with a-GalCer [46] [47] [48] . Macaques are a useful primate model to study NKT cells [11, 12, 49, 50] ; however, to our knowledge no studies have assessed NKT cell activation or expansion strategies using a-GalCer in macaques. Therefore, we sought to determine simple yet effective ways to achieve this with pigtail macaque NKT cells in vivo.
Twenty-seven healthy macaques were assigned randomly to be given 1-100 mg a-GalCer (KRN7000) by i.v. injection, pulsed onto ex-vivo WB or pulsed onto autologous PBMC for defined periods (Table 1 , Figs 1 and 2 ). a-GalCer was well tolerated by all 27 macaques, as no systemic or local clinical manifestations were observed. CD1d tetramers loaded with the a-GalCer analogue, PBS-44, were used to identify NKT cells from these animals. PBS-44 is used as it loads more efficiently into CD1d tetramers, and we determined that these tetramers stained NKT cells comparably to CD1d tetramers loaded with KRN7000 (the form of this glycolipid that was administered into the animals) (Supporting information, Fig. S1 ). A pronounced reduced detection of NKT cell frequencies occurred at days 2/3 posta-GalCer delivery, regardless of the mode of administration, in animals given 10-100 mg a-GalCer (mean 0·012% NKT cells within the lymphocyte population, range 0·00-0·06% for all animals in the 10-100 mg group; mean 0·02%, range 0·00-0·06% in the PBMC group; mean 0·001%, range 0·00-0·001% in the WB group and mean 0·002%, range 0·00-0·003% in the i.v. group). This effect was less pronounced when only 1 mg a-GalCer was given (mean 0·071% NKT cells of lymphocytes, range 0·002-0·45% for all animals within the 1 mg group; mean 0·24%, range 0·03- 0·45% in the PBMC group; mean 0·02; range 0·002-0·08% in the WB group; mean 0·04%, range 0·003-0·09% in the i.v. group). In some animals, particularly those administered a-GalCer pulsed onto PBMC, there was even a slight decline in detection of NKT cell frequencies within the circulating lymphocyte population within 10 min of administration (range 3-43% reduced detection compared to baseline in 19 of 27 animals, Figs 1a,b, 2b). Although NKT cell levels illustrated variable patterns across the animals, after a-GalCer administration a common finding was that detectable NKT cell levels began to rise after the nadir at 2/3 days, reaching maximal levels between days 6-9, followed by a slight drop at days 20/21 before stabilizing. An interesting observation noted was that some animals that had higher baseline NKT cell frequencies achieved higher NKT cell expansion after a-GalCer delivery (Fig. 1b) . For example, one animal in the PBMC 1 h 1 mg group (top panel, leftmost graph) had a pre-administration NKT cell frequency of 0·4% that rose to 1·41% at day 9, while another animal in the WB 1h 1 mg group (centre panel, left-most graph) had a starting NKT cell frequency of 0·13% that rose to 0·4% after a-GalCer delivery. However, in 13 of 19 animals NKT cell levels did not return to pretreatment baseline levels at the end of the observation period of 69 days (range 4-140% of baseline numbers; median 34%). Pulsing either WB or PBMC for a longer duration (>1 h) did not increase NKT cell percentages perceptibly. Interestingly, NKT cell levels in the two animals administered 100 mg a-GalCer i.v. remained at 4-8% of baseline frequencies through to day 69, the lowest of all the animals studied. We also assessed absolute numbers of blood NKT cells over time after a-GalCer administration by measuring concurrently total lymphocyte counts. All animals in all groups had detectable, albeit variable, baseline NKT cell numbers (mean 5951 NKT cells/ml blood, range 145-21 200 NKT cells/ml blood), consistent with observations on peripheral NKT cell levels in humans, other macaque species and our previous data in pigtail macaques [1, 11, 12, 41, 49, 50] . On the whole, total NKT cell numbers in blood sampled over time mirrored NKT cell frequencies enumerated within the lymphocyte population by flow cytometry (Fig. 1b) . Across the whole cohort, average NKT cell percentages were 0·11 at 10 min and 0·03 at 2/3 days after a-GalCer administration.
Effect of dose and mode of a-GalCer administration and impact on NKT cell subsets
The PBMC mode of delivery of a-GalCer was more effective than i.v. delivery for enhancing NKT cell frequencies at days 9 and 20 across all doses ( Fig. 2b ; P = 0·001 between the PBMC and i.v. groups in a two-way anova with Bonferroni's post-hoc test). Intravenous administration of a-GalCer resulted more commonly in sustained lower frequencies of NKT cells compared to PBMC administration (P = 0·033 at day 20). WB delivery of a-GalCer was not different to the other modes of delivery for NKT cell frequencies at days 9 and 20.
A high dose of a-GalCer was detrimental for recovery of NKT cells. Animals given Ն10 mg a-GalCer had significantly lower NKT cell frequencies across days 9 and 20 (P = 0·004) compared to animals given 1 mg a-GalCer. NKT cell levels across all doses had expanded significantly by day 9 after the initial decline observed at days 2/3 (P < 0·001). a-GalCer administration, however, resulted in no overall expansion of NKT cells from baseline levels, by day 9 or later (P = 0·438) (Fig. 2b) .
To determine factors regulating the differences in NKT cell frequencies we studied the impact of delivery of a-GalCer on peripheral NKT cell subsets over time (Fig. 2c) . Our previous data from pigtail macaques showed that the major peripheral blood NKT cell subsets were CD4 +
CD8
-and CD4 -CD8 + and that the CD4 + NKT cell subset declined after SIV infection [12] . In this study, ex-vivo peripheral blood NKT cell subset frequencies across all 27 animals at day 0 were as follows: CD4 + NKT cells (mean 49%; range 16-74%), CD8
+ NKT cells (mean 40%; range 5-77%); CD4 +
+ double-positive (DP) NKT cells (mean 7·9%; range 0-29%) and CD4 -
-double-negative (DN) NKT cells (mean 1·8%; range 0-7·5%). The CD4 + , DP or DN NKT cell subset frequencies at day 9 after a-GalCer administration were not statistically different from baseline Fig. 2 . Impact of dose and mode of delivery of a-galactosylceramide (a-GalCer) and impact on peripheral NKT cell subsets. (a). NKT cell levels were normalized to baseline levels and animals were segregated according to the dose of a-GalCer (a) and dose and mode of delivery (b). Groups contained variable numbers of animals: all animals/1 mg (n = 10), peripheral blood mononuclear cells (PBMC)/1 mg (n = 2), whole blood (WB)/1 mg (n = 5), IV/1 mg (n = 3); all animals/10 mg (n = 17), PBMC/10 mg (n = 9), WB/10 mg (n = 4), intravenous (i.v.)/10-100 mg (10 mg, n = 2; 100 mg, n = 2). Two-way analysis of variance (anova) was carried out on data prior to normalization to baseline NKT cell frequencies. (c) NKT Graphs show data normalized to the respective subset frequencies measured at day 0 with some exceptions in the DP and DN graphs, where no DP or DN NKT cell subsets were detected at day 0, as follows: four animals shown in the DP graph were normalized to DP NKT cell frequencies measured at day 6, while one animal had no DP cells at any time-point; eight animals in the DN graph were normalized to DN NKT cell frequencies detected between the 10 min -day 20/21 time-point, while two animals had no DN NKT cells at any time-point. Two-way anova carried out on subset frequencies prior to baseline normalization (P Ն 0·083 between days 0 and 9 for each of CD4 + , DP or DN subsets; P < 0·007 for CD8 -subset).
Error bars, standard error of the mean; #P = 0·001 between PBMC and i.v. groups; †P = 0·03 between PBMC and i.v. groups; •P = 0·004.
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NKT cell stimulation in macaques levels (P Ն 0·083). However, the CD8 + NKT cell subset frequency was significantly lower at day 9 compared to baseline values (P = 0·007).
Activation profile of NKT cells after a-GalCer administration
In addition to numerical levels of NKT cells, the capacity of NKT cells to be activated upon stimulation may be an important measure of NKT cell function. NKT cells from the baseline time-point (day 0) activated in vitro in WB assays with PMA/ionomycin exhibited clear intracellular IFN-g staining (Fig. 3) [41] . In the absence of mitogenic PMA/ionomycin stimulation, we detected very little IFN-g production from NKT cells at days 9 and 20 after in-vivo a-GalCer administration (<4% IFN-g expression, data not shown). This is probably because, at these later time-points, the NKT cells are no longer in an activated state in response to a-GalCer challenge, which is consistent with results from studies in mice [51] . However, the peak of NKT cell expansion at day 9 did not coincide with higher levels of mitogeninduced IFN-g expression. Furthermore, IFN-g production at days 9 or 20/21 was lower than baseline levels (P < 0·001).
Effect of a-GalCer-pulsed blood as a vaccine adjuvant
a-GalCer has been shown to improve vaccine efficacy in murine studies of both influenza and herpes simplex virus vaccinations [29] [30] [31] 36] . No studies have analysed the effects of a-GalCer as a vaccine adjuvant in macaques. We evaluated the effectiveness of a-GalCer as an adjuvant in a pilot trial of two macaques given 5 mg a-GalCer delivered via peripheral blood at the same time as the first dose of live attenuated influenza virus A (flu) carrying three SIVspecific CD8 T cell epitopes [42, 43] . Macaques were reinoculated with three further doses of flu over a 19-week period, but without any further administration of a-GalCer (Fig. 4a shows the vaccination schedule) . A second cohort of eight animals were given the above regimen but without a-GalCer, and a third cohort of five animals received live attenuated flu without SIV epitopes inserted.
As observed with the administration of a-GalCer onto WB in the absence of vaccination, detection of peripheral blood NKT cell levels in the two immunized macaques declined to approximately 50% within a half hour of a-GalCer delivery, and these cells were essentially undetectable at 2 days, after which NKT cell levels begin to rise ( Fig. 4a) . However, one animal never recovered its baseline frequency of NKT cells. In contrast, no apparent depletion of NKT cells occurred in animals immunized with flu-SIV or flu-only but not given a-GalCer.
To assess whether a-GalCer had an impact on influenzaspecific immunity we studied both antibody response by HI antibody titration and influenza T cell response by MHC class I tetramer (Fig. 4b,c) . HI antibodies were observed rarely prior to 14 days after the first influenza inoculation, but thereafter HI antibodies to influenza were present in all animals and, although variable across the small numbers of animals, were of a similar magnitude in animals administered a-GalCer compared to those not administered a-GalCer.
We also studied an influenza-specific T cell response late into the flu infection, at 133 days after the first flu inoculation. We previously mapped an influenza nucleoproteinspecific CD8 T cell response (RA9) restricted by the MHC class I allele Mane-A1*08401 [42] . As all animals expressed this MHC allele, we compared the RA9-specific CD8 T cell response in animals given a-GalCer to those not given a-GalCer. The levels of RA9-specific CD8 T cells produced by animals given a single dose of a-GalCer were relatively low (0·060-0·080% of CD8 T cells) and were within the range of animals that received either flu-SIV or flu-only infections.
Pretreatment with a-GalCer does not alter SIV infection
NKT cells activated following a-GalCer delivery in mice remain in an activated state, with production of IFN-g for the first 48 h [52, 53] . Our studies showed that NKT cells are no longer detected in the peripheral blood 2 days post a-GalCer delivery, and we reasoned that at this time-point, NKT cells may be in a more activated state and primed to respond to infection. We therefore evaluated whether SIV infection or disease progression was influenced by stimulation of NKT cells with a-GalCer prior to SIV infection. We administered 5 mg a-GalCer pulsed onto peripheral blood 2 days prior to intravenous SIVmac251 infection in two naive macaques, and followed markers of SIV infection systemically in peripheral blood (Fig. 5) . Peripheral blood NKT cells were depleted in both animals as observed in the earlier studies, although not completely in one animal (Fig. 5) . NKT cell proportions returned subsequently to near baseline levels 1-2 weeks after SIV infection. SIV infection resulted subsequently in near complete depletion of NKT cells in one of the two animals, consistent with our previous analyses of total NKT cell levels following SIV infection [12] . Depletion occurred primarily in the CD4 + subset of NKT cells (Fig. 5b) . The animal that showed near complete depletion of NKT cells (red-filled square) had a 2  7  14  28  30  35  41  64  70  77  126  133  161  0   50   100   150   200   0  2  7  14  28  30  35  41  64  70  77  126  133  161   0   50   100   150   200   0  0t30'  2  7  14  28  30  35  41  64  70  77  126  133 significantly lower pretreatment baseline CD8 + NKT cell frequency of 0·61% compared to 29% in the other animal administered a-GalCer (blue-filled square), and a higher CD4
+ NKT cell frequency of 77% (cf. 51%) (data not shown). As in our previous study [12] , the proportion of CD8 + NKT cells rose concomitantly (Fig. 5c ), while variable depletion was observed in the CD4 +
CD8
+ (DP) subset (Fig. 5d ). Despite NKT cell modulation after a-GalCer administration, peripheral SIV viraemia and CD4 T cell levels were very similar between the animals administered a-GalCer to those not administered a-GalCer (Fig. 5e,f) . In addition, preliminary data carried out on these two animals found no changes in levels of serum cytokines such as IL-2, IL-4, IFN-g or TNF at 2 weeks post-a-GalCer administration compared to pre-administration levels (data not shown).
Discussion
NKT cells can be harnessed to modulate infections to microbes by exploiting their ability to enhance innate and adaptive immune responses [37] . NKT cell numbers vary widely in humans, and this may influence the ability of these cells to influence immunity (reviewed in [1, 7] ), and similar variability in NKT cell numbers is observed in macaques [12, 49, 50] . Macaques represent an important model for the study of influenza and HIV infection and immunity [42, 43, [54] [55] [56] [57] and may be a valuable means to study the impact of NKT cell activation on these diseases, and also whether NKT cell numbers can be enhanced by in-vivo activation. Therefore, we undertook a study to determine the response of macaque NKT cell activation in vivo, as well as a pilot study into the ability of NKT cell activation to enhance immune responses and/or ameliorate infection. We observed a transient reduction in detectable NKT cells within 2 days of a-GalCer administration, followed by restoration of NKT cell numbers, the extent of which appeared to vary in an a-GalCer dose-dependent manner. Thus, a low dose of 1 mg resulted in normal to increased NKT cell numbers, particularly when loaded onto PBMC, while higher doses (10-100 mg) tended towards lower NKT cell numbers compared to the starting population, regardless of the mode of delivery. Our preliminary findings failed to demonstrate an enhanced immune response to influenza or SIV infection following a-GalCer co-administration.
Presentation of a-GalCer upon APC generated in vitro with IL-2 and GM-CSF from cultured autologous PBMC was successful in elevating baseline NKT cell levels in some cancer patients [14] [15] [16] [46] [47] [48] . We determined the efficacy of introducing a-GalCer-pulsed PBMC or peripheral blood into healthy macaques without the use of long-term cultures or cytokines during the pulsing stage. Similar to previous studies in humans, expansion of NKT cells above baseline levels was observed in some but not all animals after delivery of a-GalCer either i.v., pulsed onto PBMC or pulsed onto peripheral blood. At best, a 2·5-3·5-fold expansion of NKT cells was achieved. Interestingly the two animals that had the most expansion had one of the highest baseline NKT cell frequencies. Previous studies in humans have shown a decrease in circulating numbers of NKT cells upon i.v. injection of a-GalCer, particularly at 2 days post-administration, and a lack of rebound to baseline levels [17, 58] . Our data are partially consistent with this finding, although with the caveat that the extent of rebound appears to be a-GalCer dosedependent. The early transient depletion of macaque peripheral NKT cells due to a-GalCer stimulation, also noted in mice studies, most probably reflects TCR downregulation causing NKT cells to be undetectable by CD1d tetramers [52, 53, 59, 60] . However, we cannot exclude the possibility that some of the NKT cell disappearance was due to migration from blood to other tissues. We also observed gradual long-term depletion of blood NKT cells (<75% of baseline levels) in 13 of 19 animals administered 10-100 mg a-GalCer, and followed to 10 weeks after a-GalCer administration. Again, we were unable to determine if this was due to NKT cell death or migration to other sites.
Given that, in some studies, in-vivo activation of NKT cells by a-GalCer results in an anergic response to rechallenge [51, 61] , it was also important to determine whether in-vivo activated NKT cells were still capable of producing cytokines at different time-points after a-GalCer administration. While these previously stimulated NKT cells were clearly still capable of robust IFN-g production, the percentage of cells responding was slightly but significantly lower. At the time this study was conducted, optimal methods of ex-vivo glycolipid antigenspecific activation of macaque NKT cells [41] had not been developed, so we were limited to mitogenic NKT cell activation to induce clear cytokine production. At this stage we cannot exclude the possibility that antigenspecific NKT cell activation following in-vivo a-GalCer stimulation may be different to mitogenic activation, or that expression of cytokines other than IFN-g may have correlated with expansion.
In mice, NKT cells have preformed IL-4 and IFN-g mRNA transcripts poised for immediate secretion upon ligand stimulation [62, 63] . Similarly, in macaques, the peak IFN-g expression may have occurred much earlier after in-vivo a-GalCer stimulation which would have been missed in this study, because NKT cells were essentially undetectable at days 2/3. Furthermore, in mice, in-vivo a-GalCer stimulation results in peak secretion of various cytokines such as IL-4 and IFN-g at different times after priming, which can precede peak NKT cell expansion [51, 63] . Future studies could assess additional time-points for NKT cell activation after in-vivo a-GalCer administration using IFN-g expression, expression of other cytokines and other NKT cell activation markers such as CD69, as well as the use of an exhaustion marker such as programmed death (PD)-1 [64, 65] , which may be useful in elucidating any apparent NKT cell dysfunction.
While it was encouraging that we detected a clear NKT cell response to in-vivo-administered a-GalCer, our pilot study of the impact of a-GalCer on immunity to influenza or SIV did not reveal an enhanced immune response to these viruses. It is possible that the timing of administration of a-GalCer, together with influenza vaccination (Fig. 4) or prior to SIV exposure (Fig. 5) in macaques, was suboptimal. However, studies of a-GalCer therapy in mouse models of infections were successful in clearing infection and/or augmenting T cell responses using an a-GalCer delivery timing strategy similar to that performed in our studies [29, 31, 32, [66] [67] [68] . For example, when a-GalCer was administered at the same time as irradiated sporozoites, enhanced T cell immunity to the recombinant adenovirus vector was detected [67] . Another study by the same group found that a-GalCer delivery 2 days before live sporozoite challenge cleared hepatic parasites completely [66] . In our study, we found no enhancement in CD8 T cell or antibody responses to live attenuated influenza virus after inoculation. a-GalCer may play a more useful role in augmenting CD8 T cell responses to inactivated influenza virus vaccination as noted in a mouse model [29] , compared to the live influenza infection model we studied.
In our SIV infection study of two macaques, we reasoned that NKT cells and downstream activation of effector cells may be at their peak of activation 2 days after a-GalCer administration, as evidenced by a loss of circulating NKT cells. Using this approach, however, we found no significant impact of a-GalCer delivery on the course of SIV infection. We cannot exclude the possibility that cytokine production, particularly IFN-g secretion, or bystander activation of other cell types such as APCs, necessary to combat SIV replication, may have subsided within the 48 h before infection.
There are several limitations to our study that warrant further attempts to modulate NKT cells in macaque models. First, we have not studied a-GalCer delivery via autologous DC. Although this method has been highly successful in both mice and small human cancer trials [14] [15] [16] 20, [46] [47] [48] , such methods will not be practical in diverse clinical settings. Secondly, the timing of a-GalCer delivery may not have been optimal to influence influenza or SIV-specific immunity. For example, it remains possible that NKT cells stimulated by a-GalCer would be more effective at controlling SIV if timed to coincide more closely with peak viraemia levels 2 weeks after infection. Thirdly, we did not study tissue NKT cell levels or their activation status. We observed a modest expansion of peripheral NKT cells, and we know that substantial expansion of NKT cells can occur in the spleen and liver of mice following a-GalCer administration [51, 60] . Further studies are needed to determine if trafficking and expansion may have occurred in such sites. Taken together, a more extensive study comparing the kinetics of a-GalCer administration and a broader analysis of various cytokines, bystander cell types and different tissue sources is required to determine correctly the influence of a-GalCer on influenza-or SIVspecific immunity.
In summary, we show that macaque peripheral NKT cells can be modulated safely with a-GalCer by pulsing onto PBMC or WB. Lower a-GalCer doses (<10 mg) appeared to result in better NKT cell expansion in peripheral blood than higher a-GalCer doses (10 or 100 mg). However, in preliminary experiments, we did not observe enhanced immunity to influenza or SIV infection associated with a-GalCer co-administration. Further studies are warranted to explore and optimize the impact of NKT cells on infectious diseases in macaque models.
